These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 27803638)

  • 21. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
    Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S;
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1190-7. PubMed ID: 24532785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.
    Fox RJ; Salter AR; Tyry T; Sun J; You X; Laforet G; Campagnolo D
    Int J MS Care; 2013; 15(4):194-201. PubMed ID: 24453783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
    Melis M; Cocco E; Frau J; Lorefice L; Fenu G; Coghe G; Mura M; Marrosu MG
    Neurol Sci; 2014 Mar; 35(3):401-8. PubMed ID: 23990111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis.
    Learmonth YC; Motl RW; Sandroff BM; Pula JH; Cadavid D
    BMC Neurol; 2013 Apr; 13():37. PubMed ID: 23617555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Rinaldi F; Seppi D; Calabrese M; Perini P; Gallo P
    Mult Scler; 2012 Nov; 18(11):1640-3. PubMed ID: 23100526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.
    Kamat SA; Rajagopalan K; Stephenson JJ; Agarwal S
    Patient; 2009 Jun; 2(2):105-12. PubMed ID: 22273086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
    Kappos L; Bates D; Edan G; Eraksoy M; Garcia-Merino A; Grigoriadis N; Hartung HP; Havrdová E; Hillert J; Hohlfeld R; Kremenchutzky M; Lyon-Caen O; Miller A; Pozzilli C; Ravnborg M; Saida T; Sindic C; Vass K; Clifford DB; Hauser S; Major EO; O'Connor PW; Weiner HL; Clanet M; Gold R; Hirsch HH; Radü EW; Sørensen PS; King J
    Lancet Neurol; 2011 Aug; 10(8):745-58. PubMed ID: 21777829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
    Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.
    Havla J; Gerdes LA; Meinl I; Krumbholz M; Faber H; Weber F; Pellkofer HL; Hohlfeld R; Kümpfel T
    J Neurol; 2011 Sep; 258(9):1665-9. PubMed ID: 21431380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab.
    Kaufman MD; Lee R; Norton HJ
    Mult Scler; 2011 Apr; 17(4):490-4. PubMed ID: 21135017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
    Stüve O; Cravens PD; Frohman EM; Phillips JT; Remington GM; von Geldern G; Cepok S; Singh MP; Tervaert JW; De Baets M; MacManus D; Miller DH; Radü EW; Cameron EM; Monson NL; Zhang S; Kim R; Hemmer B; Racke MK
    Neurology; 2009 Feb; 72(5):396-401. PubMed ID: 18987352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validity of performance scales for disability assessment in multiple sclerosis.
    Marrie RA; Goldman M
    Mult Scler; 2007 Nov; 13(9):1176-82. PubMed ID: 17623733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
    Polman CH; O'Connor PW; Havrdova E; Hutchinson M; Kappos L; Miller DH; Phillips JT; Lublin FD; Giovannoni G; Wajgt A; Toal M; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):899-910. PubMed ID: 16510744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.
    Kurth T; Walker AM; Glynn RJ; Chan KA; Gaziano JM; Berger K; Robins JM
    Am J Epidemiol; 2006 Feb; 163(3):262-70. PubMed ID: 16371515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.
    Hohol MJ; Orav EJ; Weiner HL
    Mult Scler; 1999 Oct; 5(5):349-54. PubMed ID: 10516779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.
    Ware J; Kosinski M; Keller SD
    Med Care; 1996 Mar; 34(3):220-33. PubMed ID: 8628042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.